EYPT Latest Press Releases

-- October 20, 2026 --

EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals PRNewswire 10:10 AM

-- October 19, 2026 --

EyePoint Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into EyePoint Pharmaceuticals (EYPT) PRNewswire 5:59 PM

EyePoint Announces Strategic Prioritization Globe Newswire 7:15 AM

EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU in Wet AMD Globe Newswire 7:00 AM

-- September 24, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT PRNewswire 5:35 PM

-- September 22, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT Globe Newswire 7:21 PM

-- September 16, 2026 --

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- September 10, 2026 --

EYPT Investigation Alert: EyePoint, Inc. Investors Encouraged to Contact Kessler Topaz Meltzer & Check, LLP Globe Newswire 12:10 PM

-- September 6, 2026 --

Investigation Alert: EyePoint, Inc. (EYPT) Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP PRNewswire 11:01 AM

-- September 4, 2026 --

EyePoint, Inc. (NASDAQ: EYPT) Alert: Investors Encouraged to Contact KTMC Law Firm Globe Newswire 9:51 AM

-- September 2, 2026 --

EYPT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving EyePoint Pharmaceuticals Globe Newswire 8:00 PM

EYEPOINT STOCKHOLDER ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm Globe Newswire 3:04 PM

EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting Globe Newswire 7:00 AM

-- September 1, 2026 --

EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations Business Wire 8:00 PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT Globe Newswire 6:27 PM

-- August 28, 2026 --

EYPT ALERT: Investigation Launched into EyePoint, Inc., Investors are Encouraged to Contact KTMC Law Firm PRNewswire 7:10 PM

EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law Business Wire 2:11 PM

-- August 27, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT PRNewswire 4:24 PM

Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm Globe Newswire 8:25 AM

-- August 26, 2026 --

EYEPOINT PHARMACEUTICALS INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud Globe Newswire 8:00 PM

NASDAQ: EYPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm Business Wire 4:51 PM

EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky PRNewswire 10:11 AM

-- August 25, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT Globe Newswire 6:19 PM

-- August 24, 2026 --

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving EyePoint Pharmaceuticals (EYPT) Globe Newswire 10:13 AM

-- August 21, 2026 --

EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT) Business Wire 10:09 AM

-- August 20, 2026 --

EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals PRNewswire 1:03 PM

-- August 17, 2026 --

EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU 2.7mg in Wet AMD Globe Newswire 7:00 AM

-- August 14, 2026 --

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 4:32 PM

-- August 5, 2026 --

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments Globe Newswire 7:00 AM

-- July 30, 2026 --

EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU for Treatment of Diabetic Macular Edema (DME) Globe Newswire 7:00 AM

-- July 16, 2026 --

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- July 13, 2026 --

EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer Globe Newswire 7:00 AM

-- June 16, 2026 --

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 7:00 AM